EC Neurology

After 3 years of the Covid-19 pandemic, it is possible to explain what impacted mostly neuromuscular patients and treating physicians. There were many challenging items, such as determining if patients with neuromuscular disease (NMD) present a higher risk for Covid-19 and determining the consequences of the risk of Covid-19 infection for treatments used in patients with NMD, it was important to find out if cases with NMD that developed after Covid-19 infection or pre-existing conditions were exacerbated. Positive effects were observations regarding vaccines for Covid-19, that did not harm neuromuscular disease, finally, teleconsultations were the most frequent types of telemedicine used during the COVID-19 in different European countries to face worsening of NMD, therapy or physical therapy advice, diagnosis, and general follow-up.

Keywords: Neuromuscular Diseases; Covid-19; Pandemic; Risk Factors; Telemedicine

1. , et al. Impact of COVID-19 on the quality of life of patients with neuromuscular disorders in the Lombardy area, Italy, Muscle and Nerve (2021).
2. Pisella LI., et al. “A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases”. Orphanet Journal of Rare Diseases 1 (2021): 450.
3. Yung-Hao Tseng and Tai-Heng Che. “Care for Patients with Neuromuscular Disorders in the COVID-19 Pandemic Era”. Frontiers in Neurology 12 (2021): 607790.
4. Angelini C and Siciliano G. “Neuromuscular diseases and Covid-19: advice from scientific societies and early observations in Italy”. European Journal of Translational Myology 2 (2020): 9032.
5. Guidon AC and Amato A. “Covid-19, and neuromuscular disorders”. Neurology 22 (2020): 959-969.
6. Angelini C. Acquired Neuromuscular Disorders (2022).
7. Suh J and Amato AA. “Neuromuscular complications of coronavirus disease-19”. Current Opinion in Neurology 5 (2021): 669-674.
8. El-Hassar L., et al. “Telemedicine in Neuromuscular Diseases During Covid-19 Pandemic: ERN-NMD”. European Survey Journal of Neuromuscular Diseases (2022).